Nabriva Therapeutics plc (NBRVF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNabriva Therapeutics plc (NBRVF) trades at $0.0001. Nabriva Therapeutics plc is a biopharmaceutical company focused on developing novel anti-infective agents for serious infections. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for NBRVF: NBRVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Nabriva Therapeutics plc (NBRVF) Healthcare & Pipeline Overview
Nabriva Therapeutics plc specializes in the development and commercialization of innovative anti-infective agents, targeting serious bacterial infections with a focus on expanding its product portfolio through advanced clinical trials.
What Is the Investment Thesis for NBRVF?
Nabriva Therapeutics plc presents a unique investment thesis driven by its innovative product pipeline and strategic focus on anti-infective therapies. With SIVEXTRO and XENLETA already on the market, the company is well-positioned to capitalize on the increasing prevalence of antibiotic-resistant infections, a significant global health challenge. The ongoing Phase I clinical trials for XENLETA and CONTEPO may unlock substantial revenue opportunities, particularly in pediatric and complicated urinary tract infection markets, which are projected to grow significantly. Furthermore, the company's negative profit margin of -160.3% highlights the potential for operational improvements as it scales its commercial activities. Investors should monitor Nabriva's progress in clinical trials and regulatory approvals, as successful outcomes could lead to substantial market penetration and revenue growth.
Based on FMP financials and quantitative analysis
NBRVF Key Highlights
Market Cap: $0.00B, reflecting the early-stage nature of the company.
- Profit Margin: -160.3%, indicating significant investment in R&D with potential for future profitability.
- Gross Margin: 19.9%, highlighting the cost structure associated with product sales.
- Beta: -0.68, suggesting lower volatility compared to the market.
- No dividend yield, consistent with a growth-focused biopharmaceutical company.
Who Are NBRVF's Competitors?
NBRVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $140.61 | -3.21% | $358B | 76 5-pillar |
| PFE Pfizer Inc. | $29.79 | -0.80% | $171B | 69 5-pillar |
| GILD Gilead Sciences, Inc. | $158.69 | +1.70% | $193B | 67 5-pillar |
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $258M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NBRVF's Key Strengths?
Innovative product offerings with potential to address serious infections.
- Experienced leadership team with a strong background in biopharmaceuticals.
- Established products with market presence, such as SIVEXTRO.
What Are NBRVF's Weaknesses?
Negative profit margin indicating significant operational costs.
- Limited workforce may constrain growth and operational capacity.
- Dependence on successful clinical trials for future revenue generation.
What Are the Key Risks for NBRVF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory delays in obtaining approvals for new products could impact timelines.
- Intense competition from established pharmaceutical companies may affect market share.
- Dependence on successful clinical trials for future revenue generation poses risks.
What Threats Does NBRVF Face?
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles that could delay product approvals.
- Market volatility affecting funding and investment opportunities.
What Are NBRVF's Competitive Advantages?
- Innovative product pipeline targeting unmet medical needs.
- Strong focus on research and development in anti-infective therapies.
- Regulatory expertise in navigating approval processes for new drugs.
What Does NBRVF Do?
Nabriva Therapeutics plc, founded in 2005 and headquartered in Dublin, Ireland, is a biopharmaceutical company dedicated to developing and commercializing novel anti-infective agents to address serious infections. Initially established as Nabriva Therapeutics Forschungs GmbH, the company rebranded in 2007 to reflect its global ambitions. Nabriva's flagship products include SIVEXTRO, an oxazolidinone-class antibacterial approved for treating acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. The company is actively pursuing the development of XENLETA for several indications, including pediatric infections, sexually transmitted infections, cystic fibrosis, and various types of pneumonia and infections related to surgical procedures. Additionally, Nabriva is advancing CONTEPO, an epoxide antibiotic targeting complicated urinary tract infections, currently in Phase I clinical trials for peri-operative prophylaxis. With a lean workforce of 39 employees, Nabriva is positioned to leverage its innovative research and development capabilities to meet the growing demand for effective anti-infective therapies worldwide.
What Products and Services Does NBRVF Offer?
- Develops novel anti-infective agents to treat serious infections.
- Commercializes SIVEXTRO, an antibacterial for ABSSSI.
- Offers XENLETA, a semi-synthetic antibiotic for oral and IV use.
- Conducts clinical trials to expand treatment indications for existing products.
- Researches new antibiotics to combat antibiotic resistance.
- Focuses on regulatory approvals for its product pipeline.
How Does NBRVF Make Money?
- Generates revenue through the sale of approved pharmaceuticals.
- Engages in partnerships for research and development funding.
- Pursues grants and funding for clinical trials and product development.
- Explores licensing agreements for product distribution and marketing.
What Industry Does NBRVF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug development and increasing demand for novel therapies to combat antibiotic resistance. The global anti-infective market is projected to expand significantly, with a focus on innovative solutions that address unmet medical needs. Nabriva Therapeutics operates within this dynamic landscape, competing with established pharmaceutical companies and emerging biotech firms. The company's focus on anti-infective agents positions it well to capture market share as healthcare providers seek effective treatments for resistant infections.
Who Are NBRVF's Key Customers?
- Healthcare providers and hospitals requiring effective anti-infective treatments.
- Pharmaceutical distributors and wholesalers.
- Patients suffering from serious bacterial infections.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Nabriva Therapeutics plc operates in the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO H. Michael Hogan. NBRVF has traded publicly since 2023.
Financial Health
Nabriva Therapeutics plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Nabriva Therapeutics plc revenue of about $163.8M for fiscal 2026, with EPS near $8.91.
NBRVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NBRVF Latest News
No recent news available for NBRVF.
NBRVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NBRVF.
Price Targets
Wall Street price target analysis for NBRVF.
NBRVF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NBRVF; grades run from A+ (80-100) to F (below 30).
Leadership: H. Michael Hogan
CEO
H. Michael Hogan has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in strategic planning and operational management, with a focus on driving growth and innovation. Hogan has successfully led teams in developing and commercializing pharmaceutical products, contributing to significant advancements in the field.
Track Record: Under Hogan's leadership, Nabriva has made substantial progress in advancing its clinical trials and expanding its product pipeline. His strategic vision has positioned the company to address critical healthcare needs, particularly in the anti-infective space.
NBRVF OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers such as OTCQX or OTCQB. These companies may have less stringent reporting requirements, leading to lower visibility in the market compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Lower liquidity compared to stocks listed on major exchanges, potentially impacting trading.
- Lack of stringent reporting requirements may result in less transparency.
- Increased volatility due to lower trading volumes and investor interest.
- Verify the company's financial health and operational metrics.
- Assess the progress of clinical trials and regulatory approvals.
- Review the management team's experience and track record.
- Examine market trends and competitive landscape.
- Investigate any legal or regulatory issues affecting the company.
- Established product offerings with market presence.
- Experienced leadership team with a strong background in pharmaceuticals.
- Ongoing clinical trials indicating commitment to innovation.
NBRVF Healthcare Stock FAQ
How does Nabriva Therapeutics plc navigate regulatory approval processes?
Nabriva Therapeutics employs a strategic approach to navigate regulatory approval processes, focusing on compliance with FDA and EMA guidelines. The company has a track record of successfully bringing products to market, leveraging its expertise in clinical trial design and regulatory submissions to facilitate timely approvals.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the latest available reports; ongoing developments may impact metrics.